Last reviewed · How we verify

Renormax (SPIRAPRIL HYDROCHLORIDE)

FDA-approved approved Small molecule Under review Quality 10/100

Renormax (generic name: SPIRAPRIL HYDROCHLORIDE) is a spirapril drug. It is currently FDA-approved (first approved 1994) for Hypertensive disorder.

Renormax is a small molecule inhibitor of the angiotensin-converting enzyme, a type of enzyme involved in regulating blood pressure. It has been studied in clinical trials for various conditions, including post-stroke pneumonia, heart diseases, diabetes, and hypertension, often in combination with other treatments such as angiotensin converting enzyme inhibitors, Calcium Channel Blockers, and Angiotensin Receptor Blockers.

At a glance

Generic nameSPIRAPRIL HYDROCHLORIDE
Drug classspirapril
TargetAngiotensin-converting enzyme
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved
First approval1994

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Renormax

What is Renormax?

Renormax (SPIRAPRIL HYDROCHLORIDE) is a spirapril drug, indicated for Hypertensive disorder.

What is Renormax used for?

Renormax is indicated for Hypertensive disorder.

What is the generic name of Renormax?

SPIRAPRIL HYDROCHLORIDE is the generic (nonproprietary) name of Renormax.

What drug class is Renormax in?

Renormax belongs to the spirapril class. See all spirapril drugs at /class/spirapril.

When was Renormax approved?

Renormax was first approved on 1994.

What development phase is Renormax in?

Renormax is FDA-approved (marketed).

What does Renormax target?

Renormax targets Angiotensin-converting enzyme and is a spirapril.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing